Updates

Emcure Ref: EPL/CS/SE/0063/2026 Date: July 22, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Update on completion of acquisition of shares of Gennova Biopharmaceuticals Limited. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation to our earlier intimation with ref no. EPL/CS/SE/0057/2026 dated July 13, 2026 (copy attached), regarding execution of Share Transfer Agreements for acquisition of 663,865 Equity Shares, constituting 12.05% of the total issued and paid up capital of Gennova Biopharmaceuticals Limited (“Gennova”), for an aggregate consideration of Rs. 2,318.7 Million, we are pleased to inform that the Company has completed the acquisition of the aforesaid shares held by individual shareholders in Gennova, thereby making Gennova a wholly owned subsidiary of the Company. The said Equity Shares have been duly credited to the Company’s demat account on July 21, 2026, after completion of requisite procedures. The above information is also available on the Company’s website at www.emcure.com You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer Membership Number: A25687 Encl: As above Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure Ref: EPL/CS/SE/0057/2026 Date: July13, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P JTowers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai 400 051 Mumbai - 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Acquisition Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (" LODR Regulations") , we wish to inform you that the Company has today, i.e., July 13, 2026, executed Share Transfer Agreements with all the individual shareholders of Gennova Biopharmaceuticals Limited(" Gennova") , a subsidiary of the Company, for acquisition of 663,865 Equity Shares, constituting 12.05% of the total issued and paid up capital of Gennova. Upon completion of the aforesaid acquisition, Gennova would become a wholly-owned subsidiary of the Company. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the LODR Regulations are provided in Annexure A, enclosed herewith. You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited AMRUTA AMITDigitallysignedbyAMRUTA AMITYANGALWAR YANGALWAR Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership Number: A25687 Encl: As above Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure Annexure A Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015: Sr. No Particulars Information a) Name of the target entity, details Gennova Biopharmaceuticals Limited, having in brief such as size, turnover etc. CIN: U24231PN2001PLC016253 and registered office at Plot No. P-1 & P-2, IT - BT Park, Phase II, M.I.D.C, Hinjawadi, Pune – 411057, Maharashtra, India (“Gennova”). Gennova is a Subsidiary of the Company, involved in the business of research and development, manufacturing and marketing of biotechnology-based products. Turnover for the Financial Year ended March 31, 2026: Rs. 4,917.42 Million PAT for the the Financial Year ended March 31, 2026: Rs. 54.25 Million Authorized Share Capital: Rs. 650,000,000/- (Rupees Six Hundred and Fifty Million only) Paid-up Share Capital: Rs. 55,113,650/- (Rupees Fifty-Five Million One Hundred Thirteen Thousand Six Hundred and Fifty only) b) Whether the acquisition would The Company currently owns 87.95% fall within related party shareholding in Gennova, a Subsidiary and transaction(s) and whether the therefore, a related party. Further, a Promoter promoter/ promoter group/ and Director of the Company is also a Director group companies have any and Member of Gennova. The relatives of such interest in the entity being Director who are Members of Gennova are also acquired? If yes, nature of interest considered related parties. and details thereof and whether the same is done at “arm’s length” The transaction shall be undertaken at arm’s length. c) Industry to which the entity being Pharmaceuticals acquired belongs Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure d) Objects and impacts of acquisition Proposed acquisition/purchase of 663,865 (including but not limited to, Equity Shares, constituting 12.05% of the total disclosure of reasons for issued and paid-up capital of Gennova from all acquisition of target entity, if its its individual shareholders, will make Gennova business is outside the main line of a wholly-owned subsidiary of the Company. business of the listed entity) Emcure has entered into Share Purchase Agreement(s) with individual shareholders. e) Brief details of any governmental Not Applicable or regulatory approvals required for the acquisition f) Indicative time period for On or before July 31, 2026 completion of the acquisition g) Nature of consideration - whether Cash Consideration cash consideration or share swap and details of the same h) Cost of acquisition or the price at An aggregate consideration of Rs. 2,318.7 Million which the shares are acquired payable in cash in one or more tranches on closing. i) Percentage of shareholding/ The existing Equity shareholding of the control acquired and/ or number Company in Gennova is 87.95%. of shares acquired Post-acquisition, the shareholding of the Company in Gennova will be 100%. j) Brief background about the entity 1. Background: acquired in terms of products/line Gennova was incorporated on June 19, 2001, of business acquired, date of as a public limited company under the incorporation, history of last 3 Companies Act, 1956, with name ‘Emcure years turnover, country in which Dragon Biotech Limited’. The said name was the acquired entity has presence subsequently changed to Emcure Biotech and any other significant information (in brief) Limited on October 23, 2001. The name ‘Emcure Biotech Limited’ was further changed to ‘Gennova Biopharmaceuticals Limited’ on February 15, 2006. 2. Products / line of business: Gennova is involved in the business of research and development, manufacturing and marketing of biotechnology-based products. Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure 3. Date of incorporation: June 19, 2001 4. Last 3 years' turnover: i) FY 2025-26 [Showing first 8,000 characters — download PDF for full document]